CorMedix preliminary Q4 revenue ~$127M, FY2025 pro forma ~$400M; CEO becomes Chairman, new CCO appointed

CorMedix Inc.

2025-FY EPS reported $2.04 vs consensus $0.83 ▲ beat (+145.0%)

Q4 2025 unaudited net revenue ~$127M; FY2025 pro forma net rev. ~$400M (incl. Melinta).
Q4 adjusted EBITDA guidance $77-81M; cash & short-term investments ~$148M.
FY2026 revenue guidance $300-320M; DefenCath rev. $150-170M; adj. EBITDA $100-125M.
CEO Todisco salary raised to $750k (from $665k); target bonus to 75% (from 65%); assumes Chairman role.
Appoints Mike Seckler as EVP & CCO; Phase 3 ReSPECT data expected Q2 2026; Analyst Day Feb 10.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.